Tolerogenic vaccine composited with islet-derived multipeptides and cyclosporin A induces pTreg and prevents Type 1 diabetes in murine model

References

• Atkinson MA, Eisenbarth GS, Michels AW. Type 1 diabetes. The Lancet. 2014;383:69–82. doi:10.1016/S0140-6736(13)60591-7.
   PubMed Web of Science ®Google Scholar
• Santamaria P. The long and winding road to understanding and conquering Type 1 diabetes. Immunity. 2010;32:437–45. doi:10.1016/j.immuni.2010.04.003.
   PubMed Web of Science ®Google Scholar
• Katsarou A, Gudbjornsdottir S, Rawshani A, Dabelea D, Bonifacio E, Anderson BJ, Jacobsen LM, Schatz DA, Lernmark Å. Type 1 diabetes mellitus. Nat Rev Dis Primers. 2017;3:17016. doi:10.1038/nrdp.2017.16.
   PubMed Web of Science ®Google Scholar
• Ueda H, Howson JMM, Esposito L, Heward J, Snook H, Chamberlain G, Rainbow DB, Hunter KM, Smith AN, Di Genova G, et al. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature. 2003;423:506–11. doi:10.1038/nature01621.
   PubMed Web of Science ®Google Scholar
• Long SA, Buckner JH. CD4(+)FOXP3(+) T regulatory cells in human autoimmunity: more than a numbers game. J Immunol. 2011;187:2061–66. doi:10.4049/jimmunol.1003224.
   PubMed Web of Science ®Google Scholar
• Bayry J, Gautier JF. Regulatory T cell immunotherapy for Type 1 diabetes: a step closer to success? Cell Metab. 2016;23:231–33. doi:10.1016/j.cmet.2016.01.010.
   PubMed Web of Science ®Google Scholar
• Roep BO, Tree TI. Immune modulation in humans: implications for type 1 diabetes mellitus. Nat Rev Endocrinol. 2014;10:229–42. doi:10.1038/nrendo.2014.2.
   PubMed Web of Science ®Google Scholar
• Herold KC, Gitelman SE, Ehlers MR, Gottlieb PA, Greenbaum CJ, Hagopian W, Boyle KD, Keyes-Elstein L, Aggarwal S, Phippard D, et al. Teplizumab (Anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset Type 1 diabetes in a randomized controlled trial metabolic and immunologic features at baseline identify a subgroup of responders. Diabetes. 2013;62:3766–74. doi:10.2337/db13-0345.
   PubMed Web of Science ®Google Scholar
• Belghith M, Bluestone JA, Barriot S, Megret J, Bach JF, Chatenoud L. TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nat Med. 2003;9:1202–08. doi:10.1038/nm924.
   PubMed Web of Science ®Google Scholar
• Mahnke K, Johnson TS, Ring S, Enk AH. Tolerogenic dendritic cells and regulatory T cells: a two-way relationship. J Dermatol Sci. 2007;46:159–67. doi:10.1016/j.jdermsci.2007.03.002.
   PubMed Web of Science ®Google Scholar
• Hammer GE, Ma A. Molecular control of steady-state dendritic cell maturation and immune homeostasis. Annu Rev Immunol. 2013;31:743–91. doi:10.1146/annurev-immunol-020711-074929.
   PubMed Web of Science ®Google Scholar
• Terness P, Oelert T, Ehser S, Chuang JJ, Lahdou I, Kleist C, Velten F, Hämmerling GJ, Arnold B, Opelz G. Mitomycin C-treated dendritic cells inactivate autoreactive T cells: toward the development of a tolerogenic vaccine in autoimmune diseases. Proc Natl Acad Sci U S A. 2008;105:18442–47. doi:10.1073/pnas.0807185105.
   PubMed Web of Science ®Google Scholar
• Boks MA, Kager-Groenland JR, Haasjes MS, Zwaginga JJ, van Ham SM, Ten Brinke A. IL-10-generated tolerogenic dendritic cells are optimal for functional regulatory T cell induction–a comparative study of human clinical-applicable DC. Clin Immunol. 2012;142:332–42. doi:10.1016/j.clim.2011.11.011.
   PubMed Web of Science ®Google Scholar
• Martin S, Agarwal R, Murugaiyan G, Saha B. CD40 expression levels modulate regulatory T cells in Leishmania donovani infection. J Immunol. 2010;185:551–59. doi:10.4049/jimmunol.0902206.
   PubMed Web of Science ®Google Scholar
• Geng S, Zhang H, Zhou X, He Y, Zhang X, Xie X, Li C, He Z, Yu Q, Zhong Y, et al. Diabetes tolerogenic vaccines targeting antigen-specific inflammation. Hum Vaccin Immunother. 2015;11:522–30. doi:10.1080/21645515.2014.1004024.
   PubMed Web of Science ®Google Scholar
• Li C, Zhou X, Zhong Y, Li C, Dong A, He Z, Zhang S, Wang B. A recombinant G protein plus cyclosporine A-based respiratory syncytial virus vaccine elicits humoral and regulatory T cell responses against infection without vaccine-enhanced disease. J Immunol. 2016;196:1721–31. doi:10.4049/jimmunol.1502103.
   PubMed Web of Science ®Google Scholar
• Reddy S, Chang M, Robinson E. Young NOD mice show increased diabetes sensitivity to low doses of streptozotocin. Ann N Y Acad Sci. 2006;1079:109–13. doi:10.1196/annals.1375.015.
   PubMed Web of Science ®Google Scholar
• Baxter AGMT. Accelerated diabetes in non-obese diabetic (NOD) mice differing in incidence of spontaneous disease. Clin Exp Immunol. 1991;85:8.
   Web of Science ®Google Scholar
• Dirice E, Kahraman S, Elpek GO, Aydin C, Balci MK, Omer A, Sanlioglu S, Sanlioglu AD. TRAIL and DcR1 expressions are differentially regulated in the pancreatic islets of STZ- versus CY-applied NOD mice. Exp Diabetes Res. 2011;2011:625813. doi:10.1155/2011/625813.
   PubMedGoogle Scholar
• Robertson JM, Jensen PE, Evavold BD. DO11.10 and OT-II T cells recognize a C-terminal ovalbumin 323–339 epitope. J Immunol. 2000;164:4706–12.
   PubMed Web of Science ®Google Scholar
• McFarland BJ, Sant AJ, Lybrand TP, Beeson C. Ovalbumin(323-339) peptide binds to the major histocompatibility complex class II I-A(d) protein using two functionally distinct registers. Biochemistry. 1999;38:16663–70.
   PubMed Web of Science ®Google Scholar
• Desreumaux P, Foussat A, Allez M, Beaugerie L, Hebuterne X, Bouhnik Y, Nachury M, Brun V, Bastian H, Belmonte N, et al. Safety and efficacy of antigen-specific regulatory T-cell therapy for patients with refractory Crohn’s disease. Gastroenterology. 2012;143:1207–17 e2. doi:10.1053/j.gastro.2012.07.116.
   PubMed Web of Science ®Google Scholar
• Bluestone JA, Herold K, Eisenbarth G. Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature. 2010;464:1293–300.
   PubMed Web of Science ®Google Scholar
• Yu H, Paiva R, Flavell RA. Harnessing the power of regulatory T-cells to control autoimmune diabetes: overview and perspective. Immunology. 2018;153:161–70. doi:10.1111/imm.12867.
   PubMed Web of Science ®Google Scholar
• Putnam AL, Brusko TM, Lee MR, Liu W, Szot GL, Ghosh T, Atkinson MA, Bluestone JA. Expansion of human regulatory T-cells from patients with type 1 diabetes. Diabetes. 2009;58:652–62. doi:10.2337/db08-1168.
   PubMed Web of Science ®Google Scholar
• Bluestone JA, Trotta E, Xu D. The therapeutic potential of regulatory T cells for the treatment of autoimmune disease. Expert Opin Ther Targets. 2015;19:1091–103. doi:10.1517/14728222.2015.1037282.
   PubMed Web of Science ®Google Scholar
• Bluestone JA, Buckner JH, Fitch M, Gitelman SE, Gupta S, Hellerstein MK, Herold KC, Lares A, Lee MR, Li K, et al. Type 1 diabetes immunotherapy using polyclonal regulatory T cells. Sci Transl Med. 2015;7:315ra189. doi:10.1126/scitranslmed.aad3106.
   PubMed Web of Science ®Google Scholar
• Veerapathran A, Pidala J, Beato F, Yu XZ, Anasetti C. Ex vivo expansion of human Tregs specific for alloantigens presented directly or indirectly. Blood. 2011;118:5671–80. doi:10.1182/blood-2011-02-337097.
   PubMed Web of Science ®Google Scholar
• Ludvigsson J, Krisky D, Casas R, Battelino T, Castano L, Greening J, Kordonouri O, Otonkoski T, Pozzilli P, Robert -J-J, et al. GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus. N Engl J Med. 2012;366:433–42. doi:10.1056/NEJMoa1107096.
   PubMed Web of Science ®Google Scholar
• Orban T, Farkas K, Jalahej H, Kis J, Treszl A, Falk B, Reijonen H, Wolfsdorf J, Ricker A, Matthews JB, et al. Autoantigen-specific regulatory T cells induced in patients with type 1 diabetes mellitus by insulin B-chain immunotherapy. J Autoimmun. 2010;34:408–15. doi:10.1016/j.jaut.2009.10.005.
   PubMed Web of Science ®Google Scholar
• Thrower SL, James L, Hall W, Green KM, Arif S, Allen JS, Van-Krinks C, Lozanoska-Ochser B, Marquesini L, Brown S, et al. Proinsulin peptide immunotherapy in type 1 diabetes: report of a first-in-man Phase I safety study. Clin Exp Immunol. 2009;155:156–65. doi:10.1111/j.1365-2249.2008.03814.x.
   PubMed Web of Science ®Google Scholar
• Alhadj Ali M, Liu YF, Arif S, Tatovic D, Shariff H, Gibson VB, Yusuf N, Baptista R, Eichmann M, Petrov N, et al. Metabolic and immune effects of immunotherapy with proinsulin peptide in human new-onset type 1 diabetes. Sci Transl Med. 2017. doi:doi:10.1126/scitranslmed.aaf7779.
   PubMed Web of Science ®Google Scholar
• Kuhtreiber WM, Tran L, Kim T, Dybala M, Nguyen B, Plager S, Huang D, Janes S, Defusco A, Baum D, et al. Long-term reduction in hyperglycemia in advanced type 1 diabetes: the value of induced aerobic glycolysis with BCG vaccinations. NPJ Vaccines. 2018;3:23. doi:10.1038/s41541-018-0062-8.
   PubMed Web of Science ®Google Scholar
• European FK506 Multicenter Liver Study Group. Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection.Lancet. 1994;344:423–28.
   PubMed Web of Science ®Google Scholar
• Dougados M, Awada H, Amor B. Cyclosporin in rheumatoid arthritis: a double blind, placebo controlled study in 52 patients. Ann Rheum Dis. 1988;47:127–33. doi:10.1136/ard.47.2.127.
   PubMed Web of Science ®Google Scholar
• Assan R, Debraysachs M, Laborie C, Chatenoud L, Feutren G, Quinioudebrie MC, Chatenoud L, Bach JF. Metabolic and immunological effects of cyclosporin in recently diagnosed Type-1 diabetes-mellitus. Lancet. 1985;1:67–71.
   PubMed Web of Science ®Google Scholar
• Laburte C, Grossman R, Abi-Rached J, Abeywickrama KH, Dubertret L. Efficacy and safety of oral cyclosporin A (CyA; Sandimmun) for long-term treatment of chronic severe plaque psoriasis. Br J Dermatol. 1994;130:366–75.
   PubMed Web of Science ®Google Scholar
• Mccaffrey PG, Luo C, Kerppola TK, Jain J, Badalian TM, Ho AM, Burgeon E, Lane WS, Lambert JN, Curran T. Isolation of the cyclosporine-sensitive T-cell transcription factor Nfatp. Science. 1993;262:750–54.
   PubMed Web of Science ®Google Scholar
• Fric J, Zelante T, Wong AYW, Mertes A, Yu HB, Ricciardi-Castagnoli P. NFAT control of innate immunity. Blood. 2012;120:1380–89. doi:10.1182/blood-2012-02-404475.
   PubMed Web of Science ®Google Scholar
• Manome H, Aiba S. Dexamethasone and cyclosporin A affect the maturation of monocyte-derived dendritic cells differently. Int Arch Allergy Immunol. 2000;122:76–84. doi:10.1159/000024406.
   PubMed Web of Science ®Google Scholar
• Tajima K, Amakawa R, Ito T, Miyaji M, Takebayashi M, Fukuhara S. Immunomodulatory effects of cyclosporin A on human peripheral blood dendritic cell subsets. Immunology. 2003;108:321–28.
   PubMed Web of Science ®Google Scholar
• Palay DA, Cluff CW, Wentworth PA, Ziegler HK. Cyclosporine inhibits macrophage-mediated antigen presentation. J Immunol. 1986;136:4348–53.
   PubMed Web of Science ®Google Scholar
• Kang Y, Xu L, Wang B, Chen A, Zheng G. Cutting edge: immunosuppressant as adjuvant for tolerogenic immunization. J Immunol. 2008;180:5172–76.
   PubMed Web of Science ®Google Scholar
• Baban B, Chandler PR, Sharma MD, Pihkala J, Koni PA, Munn DH, Mellor AL. IDO activates regulatory T cells and blocks their conversion into Th17-like T cells. J Immunol. 2009;183:2475–83. doi:10.4049/jimmunol.0900986.
   PubMed Web of Science ®Google Scholar
• Francisco LM, Salinas VH, Brown KE, Vanguri VK, Freeman GJ, Kuchroo VK, Sharpe AH. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med. 2009;206:3015–29. doi:10.1084/jem.20090847.
   PubMed Web of Science ®Google Scholar
• Unger WWJ, Laban S, Kleijwegt FS, van der Slik AR, Roep BO. Induction of Treg by monocyte-derived DC modulated by vitamin D-3 or dexamethasone: differential role for PD-L1. Eur J Immunol. 2009;39:3147–59. doi:10.1002/eji.200839103.
   PubMed Web of Science ®Google Scholar
• Turnquist HR, Raimondi G, Zahorchak AF, Fischer RT, Wang ZL, Thomson AW. Rapamycin-conditioned dendritic cells are poor stimulators of allogeneic CD4(+) T cells, but enrich for antigen-specific Foxp3(+) T regulatory cells and promote organ transplant tolerance. J Immunol. 2007;178:7018–31. doi:10.4049/jimmunol.178.11.7018.
   PubMed Web of Science ®Google Scholar
• Buckland M, Jago C, Fazekesova H, George A, Lechler R, Lombardi G. Aspirin modified dendritic cells are potent inducers of allo-specific regulatory T-cells. Int Immunopharmacol. 2006;6:1895–901.
   PubMed Web of Science ®Google Scholar
• Zhang X, Tao YZ, Wang JZ, Garcia-Mata R, Markovic-Plese S. Simvastatin inhibits secretion of Th17-polarizing cytokines and antigen presentation by DCs in patients with relapsing remitting multiple sclerosis. Eur J Immunol. 2013;43:281–89. doi:10.1002/eji.201242566.
   PubMed Web of Science ®Google Scholar
• Mallone R, Brezar V, Boitard C. T cell recognition of autoantigens in human type 1 diabetes: clinical perspectives. Clin Dev Immunol. 2011;2011:513210. doi:10.1155/2011/513210.
   PubMedGoogle Scholar
• Di Lorenzo TP. MPaBOR. translational mini-review series on Type 1 diabetes, systematic analysis of T cell epitopes in autoimmune diabetes. Clin Exp Immunol. 2007;148:16. doi:10.1111/j.1365-2249.2007.03362.x.
   Web of Science ®Google Scholar